COVID-19 and regenerative medicine: on this channel, find the latest updates and opinions on the intersection of coronavirus and regenerative medicine. Read news about potential new treatments, hear from industry insiders about how regenerative technology could be applied to treat COVID-19 plus register for live events where you'll be able to learn from experts as well as pose your own questions.

Since 2006, the award-winning peer-reviewed journal Regenerative Medicine (IF:2.868, MEDLINE-indexed) has been at the forefront of publishing the best in clinical translation, commercialization and regulation. By delivering the latest original research, reviews and opinions from leaders in the field, Regenerative Medicine continues to provide a specialist forum addressing the important challenges and advances in this rapidly evolving sector.

Read the latest journal news here, plus, exclusively for RegMedNet members, get free access to selected papers. For more information on Regenerative Medicine and to check out all the latest content, visit the journal site.

CAR-T therapy involves utilizing a patient’s own T-cells to treat cancer and, as a technique, has rapidly expanded over the past year. However, obtaining patient samples can be problematic, time-consuming and costly. To make the use of the economy-of-scale, there has been a move away from autologous therapies to allogeneic therapies, which could be used ‘off-the-shelf’, although that transition is still in its early days.

This Spotlight will aim to review the advances in CAR-T therapy, the challenges the treatment has faced and the future as we advance allogeneic alternatives. In association with CellGenix GmbH and Lonza Pharma & Biotech.

Watch these webinars and panel discussions to learn about the latest developments and technologies directly from experts within the field and to pose your own questions to the presenters.